![]() | |
Clinical data | |
---|---|
Other names | 1-Formyl-LSD; 1-Formyl-N,N-diethyllysergamide; N,N-Diethyl-1-formyl-6-methyl-9,10-didehydroergoline-8β-carboxamide |
Routes of administration | Oral; Sublingual |
Drug class | Serotonergic psychedelic; Hallucinogen |
ATC code |
|
Identifiers | |
| |
Chemical and physical data | |
Formula | C21H25N3O2 |
Molar mass | 351.450 g·mol−1 |
3D model (JSmol) | |
| |
|
1F-LSD, or 1-formyl-LSD, also known as 1-formyl-N,N-diethyllysergamide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). [1] [2] It is the 1-formyl derivative of LSD. [1] [2] [3]
The drug is assumed to act as a prodrug of LSD. [1] It produces psychedelic effects in humans similarly to LSD. [2] Effective doses have been reported to be 100 to 150 μg orally or sublingually. [2] Very little is known about the pharmacology and properties of 1F-LSD. [1]
1F-LSD was first described in the scientific literature by 2021. [2] It first emerged as a novel designer drug online in January 2019. [1] [2]
Another compound, 1‐(furan‐2‐carbonyl)‐LSD (SYN-L-005), has also been referred to as "1F-LSD". [3]